N/A N=65 Exercise in Burn Survivors: Cooling Modalities
Burn Injury
Primary: Change in Core Temperature (°C) During Control Intervention — .578; .920; .622; .885 °C
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=45 A Clinical Investigation to Evaluate Efficacy of Mepitel Ag in Partial Thickness Second Degree Burns
Burns · Wound Healing
Primary: Number of Subjects Healed at Day 14. — 35 participants
N/A N=10 An Open Single-centre Investigation Evaluating Efficacy in Second Degree Partial Thickness Burns Using a Silicone Contact Layer Containing Silver.
Wound Healing
Primary: Number of Participants With Wound Healing — 10 participants
N/A N=28 Prophylactic Bronchoscopy After Inhalation Injury in Burn Patients
Inhalation Injury · Pneumonitis · Pneumonia
Primary: All Cause Mortality — 0; 1 participants
N/A N=14 Assessment of Safety and Effectiveness of Biodegradable Temporizing Matrix in the Treatment of Deep Burn Skin Injuries
Burns
Primary: BTM 'Take' Rate — 95.22 percentage of BTM take per subject
N/A N=30 ReCell® Combined With Meshed Skin Graft in the Treatment of Acute Burn Injuries
Burns
Primary: Number of Participants With Confirmed Treatment Area Closure of RECELL-treated Wounds Compared to Control (Non-inferiority) — 24; 22; 2; 4 Participants
Phase 4 N=20 Comparison of Wound Bed Establishment in Facial Burns
Burns
Primary: Time to Wound Epithelialization — 37.4; 37.6 days — p=.0853
N/A N=54 Effectiveness of Pressure Garment Therapy After Burns
Hypertrophic Scarring After Burn Injury
Primary: Pressure Under Compression Garment — 25; 6.4 mm Hg
N/A N=3 Indocyanine Green (ICG) and SPY Imaging for Assessment of Burn Healing
Burns
Primary: Perfusion of Burned Area — 200; 100; 205; 180 % perfusion compared to normal skin
N/A N=15 Evaluation of Antimicrobial Soft Silicone, Silver Containing, Foam Dressing, Mepilex Border Ag, in Second Degree Burns
Burns
Primary: Evaluate the Experience of Using Mepilex Border Ag ( a Silver Dressing) in Normal Clinical Practice — 9 burns healed
Phase 4 N=36 Continuous Lidocaine Infusion for Management of Perioperative Burn Pain
Thermal Burns
Primary: Narcotic Consumption (Measured in mg/kg Narcotic Consumption) — 57.5; 67.75 mg/kg narcotic consumption
N/A N=130 Telemedicine Optimized Burn Intervention
Burns · Pediatric ALL
Primary: Number of Participants Who Agree to Participate in the Study — 66; 64 participants
Phase 1 N=30 StrataGraft® Skin Tissue as an Alternative to Autografting Deep Partial-Thickness Burns
Skin Wound · Burns · Trauma-related Wound
Primary: Number of Participants With Wound Closure of the Treatment Sites at Three Months — 29; 29 Participants
Phase 2 N=45 Burn Healing and Analgesia With Propranolol
Burns · Pain
Primary: Overall Pain Trajectory Slopes — -0.22; -0.16 Numeric Rating Scale Score Change/Day
Phase 3 N=30 Enteral Resuscitation Nepal (Pilot Study)
Burn Body Region Unspecified · Burn Shock
Primary: 24 Hour Average Urine Output (UOP) — 0.7; 1 ml/kg/hr
Phase 3 N=34 Effect of EGF With Silver Sulfadiazine Cream Compared With Silver Zinc Sulfadiazine Cream for Treatment of Burn Wound
Deep Partial Thickness Burn
Primary: Time of Healing by Monitoring Duration (Days) at the Beginning of Treatment and the Day of Completely Epithelialization (Complete Epithelialization Means no Open Wound…
N/A N=18 Fractional Ablative Laser Treatment for Skin Grafts
Burn Scar · Skin Graft Scar
Primary: Contracture of Scar Surface Area (Percentage of Original Area) — 97; 97 percentage
Phase 3 N=71 StrataGraft® Skin Tissue in the Promotion of Autologous Skin Regeneration of Complex Skin Defects Due to Thermal Burns That Contain Intact Dermal Elements
Burn, Thermal
Primary: Percent Area of Treatment Sites Requiring Autografting by Month 3 — 4.33; 102.10 percentage of treatment sites — p=<0.0001
N/A N=31 Effects of Transcranial Direct Current Stimulation (tDCS) on Neuropathic Symptoms Following Burn Injury
Burn Injury · Chronic Pain · Pruritus
Primary: Change in Pain Scale — 4.45; 4.19 units on a scale
N/A N=8 An Investigation to Evaluate a New Donor Site Dressing in Surgical Burn Patients
Donor Site Complication
Primary: Percentage of Participants Who Had > 95 % Epithelialization at Day 10 — 0 percentage of participants
Phase 2 N=20 Cranial Electrotherapy Stimulation in Burned Patients
Post Traumatic Stress Disorders · Burns
Primary: Mean Post-Traumatic Stress Questionnaire-Military (PCL-M) Score — 53.8; 56.7; 48.8; 50.4 Score
Phase 3 N=175 A Study to Evaluate the Efficacy and Safety of NexoBrid in Subjects With Thermal Burns
Thermal Burns
Primary: Primary Endpoint: Number of Participants With Complete Eschar Removal. — 70; 1 Participants — p=<0.0001
N/A N=53 The Effect of Neurontin on Pain Management in the Acutely Burned Patient
Pain · Burn Injury
Primary: Opioid Consumption Between the Treatment and the Control Groups (Morphine Equivalents) — 7.0; 6.7 morphine equivalents — p=<0.05
N/A N=29 Fractionated Carbon Dioxide Laser and Burn Scar Contractures: Evaluation of Post-Treatment Scar Function and Appearance
Burn Scars
Primary: Scar Pigmentation, Baseline vs 15-months — 50.93; 49.59 units on a scale
N/A N=101 A Multicenter Comparative Study of the ReCell Device and Autologous Split-thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries
Burns
Primary: Incidence of RECELL-treated Area Closure Compared to Control at 4 Weeks (Non-inferiority) — 82; 87; 82; 83 Participants
Phase 4 N=10 Effects of Intramuscular Oxytocin on Sensory Function in Healthy Volunteers With Ultraviolet Burn Injury to the Skin
Chronic Pain
Primary: Change in Vibration Frequency Detection Threshold (When Vibration is First Felt) After IM Injection — 22; 21 Hz — p=0.83
N/A N=52 Investigation of the Clinical Performance of Biatain Fiber Ag on Burns
Partial-thickness Burn
Primary: Percentage of Wounds Healed Within 14 Days — 83.7; 74.8; 70.6 percentage of wounds healed
N/A N=76 Continued Access to the Recell® Device for Treatment of Acute Burn Injuries
Burns
Primary: Percentage of Participants With Wound Healing — 95.3 percentage of participants
Phase 4 N=34 Lidocaine For Treatment of Post-operative Pain From Donor Sites Following Burn Injury.
Pain
Primary: Pain Change — -3.8; -4.0 units on a scale — p=<0.05
N/A N=24 Evaluation of Post-Exposure Sauna Treatment of Firefighters - A Pilot Study
Post-fire Rehabilitation of Firefighters in Sauna
Primary: Urinary Excretion of Hydroxylated PAHs (PAH-OHs) — 10364.2; 40012.1; 6964.1; 22604.3 ng/L — p=0.0000009